NSEAllotment of Securities8 Jul 2026 · 8 Jul 2026, 12:57 pm

Allotment of Securities

Suven Life Sciences Limited · SUVEN

✦ AI SummaryFundraise

Suven Life Sciences Limited has informed the Exchange regarding allotment of 18570133 securities pursuant to Convertible Securities at its meeting held on July 08, 2026. The company has received 100% consideration amount aggregating to Rs. 248,83,97,822/- in compliance with SEBI (ICDR) Regulations, 2018. The paid-up equity share capital of the company stands increased to Rs. 28,25,62,686/-.

Analysis Scores

Earnings Impact5/10
Growth Catalyst3/10
Governance Concern2/10
Regulatory Risk1/10
Balance Sheet Risk4/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Suven Life Sciences Limited has informed the Exchange regarding allotment of 18570133 securities pursuant to Convertible Securities at its meeting held on July 08, 2026

Attachments (1)

📄

SUVEN_08072026125643_BMoutcome08072026.pdf

pdf

Download →
View document text
CSD/BM/SE/2026-27 Date: July, 08, 2026 To To Department of Corporate Services Listing Department BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 530239 Scrip Symbol: SUVEN Dear Sir/Madam, Sub: Outcome of the Meeting of Board of Directors Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015, as amended and other applicable provisions of law, this is to inform that the Board of Directors of the Company, at its meeting held today i.e. July 08, 2026, has inter-alia considered and approved the following: 1. Allotment of 1,85,70,133 Equity Shares of the Company on preferential basis upon conversion 1,85,70,133 fully paid warrants The Board of Directors has approved Conversion of 1,85,70,133 fully paid warrants and issued & allotted 1,85,70,133 (One Crore Eighty-Five Lakhs Seventy Thousand One Hundred thirty- three only) Equity Shares of Rs.1/- each to the following Non-Promoter Persons/ Entities at an issue price of Rs. 134/- per share on preferential basis in accordance with SEBI (Issue of Capital and Requirements) Regulations, 2018. Sl. No. Non-promoter persons/entities No. of Equity shares allotted 1. TEJAS TRIVEDI 37,31,343 2. KETAN CHHOTALAL SHETH 20,00,000 3. ITI HOLDINGS AND INVESTMENT PRIVATE LIMITED 18,65,670 4. ARUN NAHAR 15,00,000 5. JAGDISH N MASTER 15,00,000 6. NILESH KISHORE SHAH 12,00,000 7. NIMESH ARVIND DOSHI 11,94,100 8. ORACULAR ADVISORY PRIVATE LIMITED 11,25,000 Suven Life Sciences Limited Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com 9. ATMAN INVESTMENTS PRIVATE LIMITED 10,00,000 10. ZAPFIN TEKNOLOGIES PRIVATE LIMITED (Formerly, 10,00,000 Trishakti Power Holdings Private Limited) 11. TIKRI PARTNERS LLP 7,46,260 12. CAMPBELL ADVERTISING PRIVATE LIMITED 4,47,760 13. NIMISH CHANDULAL SHAH 3,60,000 14. SHARAD NANDLAL SHAH 3,00,000 15. NEHA IYENGAR 3,00,000 16. SHANTIKUMAR GIRDHARLAL SHAH 1,50,000 17. CHARU MAHENDRA PARIKH 1,50,000 Total 1,85,70,133 Further it is informed that the Company has received from the above said allottees 100% consideration amount aggregating to Rs. 248,83,97,822/- in compliance with SEBI (ICDR) Regulations, 2018. Consequently, the paid-up equity share capital of the company stands increased to the following: Particulars No. of Equity Amount in INR Shares Pre-issue subscribed & paid-up capital 263992553 26,39,92,553/- Post-issue subscribed & paid-up capital 282562686 28,25,62,686/- Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025- CFDPOD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as Annexure A. 2. Re-appointment of Independent Director Based on the recommendation of the Nomination and Remuneration Committee in its meeting held today i.e. 08th July, 2026, the Board of Directors has approved the re-appointment of Dr. Vajja Sambasiva Rao (DIN: 09233939) as Non-Executive Independent Director of the Company for a second term of Five (5) years w.e.f. 21st January, 2027 to 20th January, 2032, subject to approval of the Members of the Company at the ensuing Annual General meeting. Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025- CFDPOD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as Annexure B. Suven Life Sciences Limited Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com 3. Incorporation of Wholly owned Subsidiary (WOS) In Singapore Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as Annexure C The Board Meeting commenced at 11:50 A.M (IST) and concluded at 12:35 P.M (IST). This is for your information and records. Thanking you. Yours faithfully, For Suven Life Sciences Limited K. Sangeetha Laxmi Company Secretary and Compliance officer Encl: as above Suven Life Sciences Limited Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com ANNEXURE A Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Sl. Particulars Details a) Type of securities proposed to Fully paid-up equity shares upon conversion of warrants be issued (viz. equity shares, convertibles etc.); b) Type of issuance (further public Preferential Allotment in accordance with Chapter V of the offering, rights issue, depository SEBI (ICDR) Regulations, 2018 and other applicable law. receipts (ADR/ GDR), qualified institutions placement, preferential allotment etc.); c) Total number of securities 1,85,70,133 Equity Shares of face value of Rs. 1/- each proposed to be issued or the pursuant to conversion of 1,85,70,133 warrants at an issue total amount for which the price of ₹ 134/- per warrant, for an aggregate consideration securities will be issued of Rs. 248,83,97,822/- to below allottee. (approximately); d) In case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s): i. number of investors; 17 ii. names of the investors; Sl. Non-Promoter entities/ No. of Equity No Persons Shares allotted 1 TEJAS TRIVEDI 37,31,343 2 KETAN CHHOTALAL SHETH 20,00,000 3 ITI HOLDINGS AND 18,65,670 INVESTMENT PRIVATE LIMITED 4 ARUN NAHAR 15,00,000 5 JAGDISH N MASTER 15,00,000 6 NILESH KISHORE SHAH 12,00,000 7 NIMESH ARVIND DOSHI 11,94,100 8 ORACULAR ADVISORY PRIVATE 11,25,000 LIMITED 9 ATMAN INVESTMENTS PRIVATE 10,00,000 LIMITED 10 ZAPFIN TEKNOLOGIES PRIVATE LIMITED (Formerly, Trishakti 10,00,000 Power Holdings Private Limited) 11 TIKRI PARTNERS LLP 7,46,260 12 CAMPBELL ADVERTISING 4,47,760 PRIVATE LIMITED 13 NIMISH CHANDULAL SHAH 3,60,000 14 SHARAD NANDLAL SHAH 3,00,000 15 NEHA IYENGAR 3,00,000 Suven Life Sciences Limited Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com 16 SHANTIKUMAR GIRDHARLAL 1,50,000 SHAH 17 CHARU MAHENDRA PARIKH 1,50,000 iii. post allotment of securities - Pursuant to conversion, the issued, subscribed and paid-up outcome of the subscription equity share capital of the Company stands increased to Rs. 282562686/- consisting of 282562686 fully paid-up equity shares of Rs. 1/- each. iv. issue price/ allotted price Rs. 134/- per share (in case of convertibles) v. in case of convertibles - Allotment of 18570133 equity shares pursuant to the intimation on conversion of conversion of warrants at an issue price of Rs. 134/- each securities or on lapse of the (face value of Rs. 1/- each and premium of Rs. 133/- each) tenure of the instrument; upon receipt of 100% consideration amount from above mentioned allottee amounting to Rs. 248,83,97,822/- e) any cancellation or termination Not applicable of proposal for issuance of securities including reasons thereof. Suven Life Sciences Limited Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com ANNEXUR [Showing first 8,000 characters — download PDF for full document]